This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Touati, G. Articles by Czernichow, P. Search for Related Content PubMed PubMed Citation Articles by Touati, G. Articles by Czernichow, P.

Beneficial Effects of One-Year Growth Hormone Administration to Children with Juvenile Chronic Arthritis on Chronic Steroid Therapy. I. Effects on Growth Velocity and Body Composition¹

Hôpital Robert Debré (G.T., M.N.), Paris, France 75019; Hôpital Necker-Enfants Malades (A.M.P.), Paris, France; Hôpital Cochin (J.C.R.), Paris, France

Address all correspondence and requests for reprints to: Dr. Guy Touati, Centre d’Investigation Clinique, Hôpital Robert Debré, 48 Boulevard Sérurier, 75019 Paris, France.

Severe growth retardation and profoundly altered body composition are observed in children with systemic forms of juvenile chronic arthritis receiving glucocorticoids. The purpose of this study was to assess the effects of recombinant human GH (rhGH) on growth velocity (GV) and body composition studied by dual-energy X-ray absorptiometry, during a 1-yr treatment course, together with potential adverse effects on glucose tolerance. Fourteen patients were treated with rhGH (1.4 U/kg per week) for 1 yr and were then studied for a 2nd yr off GH.

Baseline GH secretion, GH binding protein (BP), insulin-like growth factor-I (IGF-I), and IGFBP3 levels were at the lower limit of normal. The rhGH treatment increased IGF-I and IGFBP3 plasma levels to above-normal values. All patients showed an increase in GV, and mean GV increased from 1.9–5.4 cm/yr (P < 0.001). Compared with the value on day 0, lean body mass increased by 12.2% (P < 0.01), and the fat mass excess fell by 19.5% (P < 0.01). Decreased glucose tolerance (as determined by oral glucose tolerance test) and increased glycosylated hemoglobin levels were observed during treatment. This effect may be attributed to insulin resistance, as reflected by induced hyperinsulinemia.

Eleven children were monitored for 1 yr after the cessation of GH therapy. GV fell to pretreatment values, whereas height in SD score at the end of the 2nd yr was lower (P < 0.01) than before treatment. Weight and fat mass again increased markedly. Although long-term controlled studies are needed to assess the risks and benefits of GH therapy in this setting, our results suggest that rhGH may partially counteract the adverse effects of glucocorticoids on growth and metabolism in patients with chronic inflammatory disease.

This article has been cited by other articles:

				S. Bechtold, P. Ripperger, R. D. Pozza, W. Bonfig, R. Hafner, H. Michels, and H. P. Schwarz Growth Hormone Increases Final Height in Patients with Juvenile Idiopathic Arthritis: Data from a Randomized Controlled Study J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3013 - 3018. [Abstract] [Full Text] [PDF]

				D. Simon, A.-M. Prieur, P. Quartier, J. Charles Ruiz, and P. Czernichow Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2567 - 2573. [Abstract] [Full Text] [PDF]

				J. A. P. DA SILVA, J. W. G. JACOBS, and J. W. J. BIJLSMA Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears Ann. N.Y. Acad. Sci., June 1, 2006; 1069(1): 275 - 288. [Abstract] [Full Text] [PDF]

				V. E. MacRae, C. Farquharson, and S. F. Ahmed The pathophysiology of the growth plate in juvenile idiopathic arthritis Rheumatology, January 1, 2006; 45(1): 11 - 19. [Abstract] [Full Text] [PDF]

				F K Grote, L W A Van Suijlekom-Smit, D Mul, W C J Hop, R Ten Cate, W Oostdijk, W Van Luijk, C J A Jansen-van Wijngaarden, and S M P F De Muinck Keizer-Schrama Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia Arch. Dis. Child., January 1, 2006; 91(1): 56 - 60. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				S. Bechtold, P. Ripperger, D. Muhlbayer, H. Truckenbrodt, R. Hafner, O. Butenandt, and H. P. Schwarz GH Therapy in Juvenile Chronic Arthritis: Results of a Two-Year Controlled Study on Growth and Bone J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5737 - 5744. [Abstract] [Full Text] [PDF]

				J. B. Q. Quintos, M. G. Vogiatzi, M. D. Harbison, and M. I. New Growth Hormone Therapy Alone or in Combination with Gonadotropin-Releasing Hormone Analog Therapy to Improve the Height Deficit in Children with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1511 - 1517. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				E. Canalis Editorial: Inhibitory Actions of Glucocorticoids on Skeletal Growth. Is Local Insulin-Like Growth Factor I to Blame? Endocrinology, July 1, 1998; 139(7): 3041 - 3042. [Full Text] [PDF]